

MedLife makes public the signing of its largest transaction for this year Neolife Medical Center Romania: "As we already briefed our shareholders
earlier this year, Oncology and Radiotherapy are to become a strategic target
for us. We want to offer patients in Romania integrated diagnostic and
treatment services to beat cancer"

- MedLife signs the agreement to acquire 50% of the Neolife Oncology Centers stock in Romania.
- This acquisition is an important step in the development of Oncology at group level, Neolife being a strong name in Radiation Oncology and Nuclear Medicine market in Turkey, Romania, and in the region, with exceptional results for Romanian patients.
- The Neolife team has succeeded in developing excellent Radiation Oncology and Nuclear Medicine services in the neighbouring countries such as Bulgaria, and the Republic of Moldova. MedLife in partnership with Neolife aims to further develop partnerships abroad.
- MedLife is working on 2 or 3 other important M&A transactions, in the Oncology area and to strengthen its network at the national level.
- The MedLife Group will continue to invest heavily in the growth of its network in Romania. This is already much bigger than any other private network, with a far superior coverage at country level and in Bucharest.

*Bucharest, October 27 2021:* the MedLife Medical System confirms today the acquisition of 50% of the shares of the Neolife Romania oncology centers, one of the largest medical players in the Oncology segment in Romania and a household name in Eastern Europe. According to company representatives, the transaction is to be vetted by the Competition Council.

The Neolife Oncology Center Romania, has been operating for seven years in the Romanian market. It operates four medical centers and is a member of the Bozlu Group, Turkey, which owns 21 companies. It has been operating in the field of healthcare and technological services for 32 years. The Neolife brand's experience in nuclear medicine dates back to 1989 when the first private company providing such services in a hospital was opened in Turkey. Just one year later, in 1990, the first stand-alone private center was opened. Since then, its development has been very fast, and now cancer diagnosis and treatment services are provided in more than 60 public and private hospitals in Turkey.

"Neolife is an innovator in medicine, they introduced revolutionary diagnostic and treatment techniques and equipment in Romania, and the expertise they have in the most advanced European protocols for the treatment of diseases places the company in the top of the field. MedLife always brings together leaders, businesses and people who do their jobs extraordinarily well, and by this partnership with Neolife, we are once again reinforcing our long-term commitment to expanding our offer of excellent medical services benefiting patients all over the country. Furthermore, given the expertise and excellence in Radiotherapy and Nuclear Medicine developed by Neolife in neighbouring countries such as Bulgaria and Moldova in the future we aim to develop partnerships beyond Romania. Moreover, we have found an excellent management team there and we want them to stay with us to strengthen the Oncological Diagnosis and Treatment Services at group level," said Mihai Marcu.

Neolife brand (managed by MNT Healthcare Europe entered the Romanian market in 2014 when it successfully launched the first oncology center in Bucharest providing diagnostic and treatment services. Neolife Medical Center Bucharest (Baneasa) is mainly equipped with two highly competitive Varian linear accelerators for Radiotherapy and Radiosurgery, a Brachytherapy system, a strong Nuclear Medicine department (PET-CT and Scintigraphy) and a high-performance Chemotherapy section.

In 2016, the 2<sup>nd</sup>, Neolife Oncology Center was opened în Iași, offering the same range of diagnosis and treatment services. Three years later the 3<sup>rd</sup> center, Neolife Medical Center Brasov, the first nuclear medicine center (PET-CT) in Brasov, was opened. Neolife opened its 4<sup>th</sup> Oncology Diagnostic and Treatment Center in Summer 2021, also located in Bucharest (Enayati Medical City). In this center, patients



have access to PET-CT diagnosis and oncological radiotherapy treatment with Varian's innovative new and powerful platform, Halcyon 3.0.

In all these years, tens of thousands of procedures have been carried out and more than 170,000 patients have been treated at Neolife centers around Romania. Patients have had access to chemotherapy or radiotherapy treatments, covered by the National Health Insurance House (NHIH) within the National Oncology Programme.

Ismail Dernek, CEO of MNT Healthcare Group, said "As an innovative healthcare company, focusing on oncological diagnostics and treatment for over 30 years, we are on a mission to provide precision medicine to cancer patients with the latest technologies and methods such as theranostics. MNT's Neolife Oncology Centers have been proudly providing state of the art cancer diagnosis and treatment to Romanian patients since 2014, growing steadily. And today, we are honoured by this partnership with MedLife, the leader in private medicine in Romania which will provide an even stronger foundation for the Neolife model. Since Neolife's entry into the local market, we have positioned ourselves as a leader in our segment, promoting innovative projects and cutting-edge professional expertise in the oncological healthcare. Together, as partners we will be able to expand the medical infrastructure, increase oncology patients' access to quality services, and thus contribute to Romanians' health and grow together in Central and Eastern Europe."

Mr.Dernek added "We have an exceptional multidisciplinary team led by our Country Manager Fabio Razzetto and state-of-the-art technology, and together with MedLife, I have no doubt that we will become leaders in the Oncology segment and one of the referred to clinics in the healthcare market in Central and Eastern Europe."

The Neolife Medical Center Romania, with a total of 250 employees and partners, closed 2020 with a turnover of 92 million lei, an increase of over 30 % as compared to 2019.

"MedLife is working on 2 or 3 other important M&A transactions, in the Oncology area to strengthen its network at the national level. It is important for us to let the people know that in the coming years we will continue to partner with other companies, at a high level, and that we have an increased appetite to cross borders. As a Romanian-owned healthcare operator that has dominated the private healthcare market for over ten years, it is now the time to show that we can become an operator with Balkan and regional ambitions. The fact that Romanians want to be treated by Romanian doctors and look for local products and services, including in healthcare, is an important message for the local market as a whole, and of course for the only company with Romanian capital in the top three local healthcare services companies. This consumer trend is not a protectionist one but, on the contrary, a natural balance that can be noticed all over Europe. It is healthy for a working economy to have a balanced combination of domestic capital and foreign investment.

We are investing massively to expand our network in Romania, a network already much larger than any other private network, with a far superior coverage at county level and in Bucharest. We want our subscribers, whether individuals or employees of our partner companies, to know that there is now a network, and the only one that they can reach by car in up to one hour, no matter where they are, at home, on holiday or on business", said Mihai Marcu.